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VEGF (vascular endothelial growth factor) plays an essential
role in angiogenesis during development and in disease largely
mediated by signalling events initiated by binding of VEGF to
its receptor, VEGFR2 (VEGF receptor 2)/KDR (kinase insert
domain receptor). Recent studies indicate that VEGF activates
PKD (protein kinase D) in endothelial cells to regulate a variety
of cellular functions, including signalling events, proliferation,
migration and angiogenesis. To better understand the role of
PKD in VEGF-mediated endothelial function, we characterized
the effects of a novel pyrazine benzamide PKD inhibitor CRT5
in HUVECs (human umbilical vein endothelial cells). The
activity of the isoforms PKD1 and PKD2 were blocked by this
inhibitor as indicated by reduced phosphorylation, at Ser
916 and
Ser
876 respectively, after VEGF stimulation. The VEGF-induced
phosphorylation of three PKD substrates, histone deacetylase
5, CREB (cAMP-response-element-binding protein) and HSP27
(heat-shock protein 27) at Ser
82, was also inhibited by CRT5.
In contrast, CRT6, an inactive analogue of CRT5, had no
effect on PKD or HSP27 Ser
82 phosphorylation. Furthermore,
phosphorylation of HSP27 at Ser
78, which occurs solely via
the p38 MAPK (mitogen-activated protein kinase) pathway,
was also unaffected by CRT5. In vitro kinase assays show
that CRT5 did not signiﬁcantly inhibit several PKC isoforms
expressed in endothelial cells. CRT5 also decreased VEGF-
induced endothelial migration, proliferation and tubulogenesis,
similar to effects seen when the cells were transfected with
PKD siRNA (small interfering RNA). CRT5, a novel speciﬁc
PKD inhibitor, will greatly facilitate the study of the role of PKD
signalling mechanisms in angiogenesis.
Key words: angiogenesis, CRT5 inhibitor, endothelium, protein
kinase C (PKC), protein kinase D (PKD), vascular endothelial
growth factor (VEGF).
INTRODUCTION
PKDs (Protein kinase Ds) are DAG (diacylglycerol)-stimulated
serine/threonine protein kinases, originally classiﬁed as a sub-
groupofthePKC(proteinkinaseC)family[1,2]butsubsequently
recognized to be a distinct subgroup of the calcium/calmodulin-
dependent protein kinase family [3], only sharing signiﬁcant
homology to PKCs in the DAG-binding domain.
TherearecurrentlythreeknownPKDisoforms:PKD1–PKD3.
All three isoforms share the same basic structure consisting of a
variable N-terminal regulatory domain and a C-terminal kinase
domain, the latter with over 90% similarity between the isoforms
[4]. PKD2 differs from PKD1 in having a serine-rich linker
between the two N-terminal zinc-ﬁnger domains, present in all
three isoforms, whereas PKD3 lacks the alanine- and proline-rich
hydrophobicdomainfoundattheN-terminusofPKD1andPKD2.
ActivationofPKDcanoccurbymultiplepathways,theprimary
one being non-classical PKC-dependent activation [5,6] resulting
from phosphorylation at serine residues within the catalytic
domain (Ser
744/Ser
748 in mouse PKD1, equivalent to Ser
738/Ser
742
inhumanPKD1)[7],whichoccursatthecellmembranefollowing
recruitment of both PKD and PKC by DAG. On PKD1 and
PKD2, but not PKD3, there is also an autophosphorylation
site near the C-terminus (Ser
916/Ser
876 in PKD1 and PKD2
respectively), which determines PKD tertiary structure and
appears to be important for its interaction with other proteins,
including 14-3-3 and PDZ proteins. PKD is predominantly
localized in the cytosol, but can be translocated to the nucleus
[8] or Golgi [4] after activation at the plasma membrane. The
substrateconsensussequenceforPKD-mediatedphosphorylation
is LXR(Q/K/E/M)(M/L/K/E/Q/A)S*XXXX, including a strong
preference for a leucine residue at the −5 position, and several
target proteins have previously been identiﬁed including HSP27
(heat-shock protein 27), HDAC (histone deacetylase) 5 and
HDAC7 [9–12].
PKD has been implicated as a mediator in diverse cellular
functions, including proliferation, survival, cellular trafﬁcking
and regulation of transcription. In endothelial cells PKD is
activated by VEGF (vascular endothelial growth factor, also
known as VEGF-A), an essential angiogenic factor, during
development and in the pathogenesis of human pathologies,
including cancer and eye diseases [13,14]. There is growing
evidencethatendothelialcellularresponsestoVEGFaremediated
atleastinpartthroughPKD[15].WepreviouslyshowedthatPKD
is required for VEGF-mediated endothelial migration and tube
formation [10], and other studies have demonstrated the role of
PKD in VEGF-induced phosphorylation of HDACs, proliferation
and migration [11,12]. Given the importance of PKD in
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VEGF-mediatedangiogenesis,apharmacologicalinhibitorwould
be a valuable biological tool for further investigation of PKD-
mediated signalling, and could also give rise to novel anti-
angiogenic therapeutics. A recent study described the effects of a
speciﬁc PKD inhibitor in cancer cells [16], although subsequent
work indicates that this compound is probably not speciﬁc
for PKD [17]. In the present study we have characterized a
novel speciﬁc PKD inhibitor CRT5 and investigate its effects
on angiogenic processes in endothelial cells.
MATERIALS AND METHODS
Materials
VEGF-A165 was from R&D Systems. SB203580 and
GF109203X were from Calbiochem. Antibodies against
total ERK (extracellular-signal-regulated kinase) 1 and
2, total PKD, phospho-PKD (Ser
744/Ser
748), phospho-PKD1
(Ser
916), total CREB (cAMP-response-element-binding protein),
phospho-CREB(Ser
133),totalHSP27andphospho-HSP27(Ser
82)
were from Cell Signaling Technology. The antibody against
phospho-HSP27 (Ser
78) was from Upstate Biotechnology, and
the antibody against phospho-PKD2 (Ser
876) was from Universal
Biologicals. The antibodies against total and phospho-HDAC5
(Ser
498) were obtained from Insight Biotechnology and Autogen
Bioclear respectively. CRT5 was synthesized in-house at Cancer
Research Technology [18]. CRT6 is a CRT5 analogue with the
same core chemical structure indicated in [18]. All other reagents
were of the highest grade available.
Cell culture
HUVECs (human umbilical vein endothelial cells) were obtained
from TCS CellWorks and were cultured on gelatin-coated
plates in EBM (endothelial basal medium; Cambrex BioScience)
supplemented with gentamycin–ampicillin, EGF (epidermal
growth factor), bovine brain extract (Singlequots; Cambrex
BioScience) and 10% (v/v) FBS (fetal bovine serum) (complete
EBM). For experimental purposes, fully conﬂuent HUVECs at
passages 2–4 were pre-incubated overnight with 0.5% FBS in
EBM prior to addition of factors and other treatments.
Compound screening, kinase proﬁling and IC50 determination
Initially, inhibitors of PKD were identiﬁed by screening
compounds for their ability to inhibit PKD1 in an in
vitro kinase assay using a puriﬁed recombinant His6-tagged
PKD1 kinase domain expressed in baculovirus (provided by
Dr Harold Jefferies, Cancer Research UK London Research
Institute, London, U.K.) and an IMAP (immobilized metal-ion-
afﬁnity-based ﬂuorescence polarization) detection system (MDS
Analytical Technologies). Compound libraries were obtained
from the following companies: Maybridge, AsInEx, Bionet
Research, Chembridge, Interbioscreen and Specs. Brieﬂy, 12 nM
recombinant PKD1 kinase domain [in 20% (v/v) glycerol] was
mixed with 200 nM substrate {recombinant MAKAPK2 [MAPK
(mitogen-activated protein kinase)]-activated protein kinase 2;
MDS Analytical Technologies} and compound for screening
[1.2 μM in DMSO; ﬁnal DMSO concentration of 4% (v/v)] in
assay buffer (25 mM Hepes, pH 7.5, and 2 mM MgCl2). ATP
was then added (10 μM ﬁnal concentration) in a total assay
volumeof30 μl.Theassaymixturewasincubatedfor1 hatroom
temperature (21◦C) followed by the addition of 20 μlo fI M A P
binding solution (MDS Analytical Technologies) and a further
2 h room temperature incubation in the dark. The ﬂuorescence
was then read on an Analyst HT plate reader (MDS Analytical
Technologies).
Speciﬁcity of CRT5 was determined by in vitro kinase assays
using a commercial kinase proﬁling service (Millipore). The IC50
values for CRT5 inhibition with PKD1–PKD3 were determined
in vitro using IMAP. Brieﬂy, 1 nM recombinant active PKD [in
20% (v/v) glycerol and assay buffer] was mixed with 200 nM
recombinant MAKAPK2 and CRT5 (0.1 nM–1.2 μM) in a total
volume of 5 μl in assay buffer. After the addition of 10 μM
ATP (in assay buffer), the mixture was incubated for 1 h at room
temperature, followed by the addition of 20 μl of IMAP binding
solution and a further 2 h of incubation at room temperature in
the dark. The ﬂuorescence was then read on an Analyst HT plate
reader.
Cell viability assay
HUVECs were seeded in a 96-well plate at a density of
1.5×10
4 cells/well. Cells were incubated with the PKD
inhibitor CRT5 (5 nM–100 μM) in complete EBM. After 24 h
0.5 mg/ml MTT [3-(4,5-dimethylthiaziazol-2-yl)-2,5-diphenyl-
2H-tetrazolium bromide] was added to each well and incubated
for a further 4 h. The medium was then removed and the cells
were washed twice with PBS, followed by the addition of 200 μl
of DMSO. After 15 min the resulting colour intensity was read at
570 and 650 nm.
Immunoblotting
Cells were pre-treated with inhibitors in serum-free medium
for 30 min, followed by a 10 min treatment with VEGF.
After treatments, cells were washed with PBS and lysed in
buffer containing 50 mM Tris/HCl, pH 7.4, 150 mM NaCl,
1 mM disodium EDTA, 1% (v/v) Igepal CA-630, 0.5%
sodium deoxycholate and 0.1% SDS, and supplemented with
phosphatase inhibitor cocktails SigmaPhos 1 and 2, and
Complete
TM protease inhibitor cocktail (Roche Diagnostics).
Whole-cell lysates were homogenized by brief sonication, then
SDS/PAGE sample buffer [62.5 mM Tris/HCl, pH 6.8, 100 mM
DTT (dithiothreitol), 2% (w/v) SDS, 10% (v/v) glycerol and
0.002% Bromophenol Blue] was added and the sample was
heated to 95–100◦C for 3 min. Equivalent amounts of protein
were separated by SDS/PAGE and transferred on to PVDF
membranes (Millipore). Membranes were blocked with 5%
(w/v) non-fat dry milk in 0.1% Tween 20 in PBS, for 1–2 h
at room temperature, before being probed with the primary
antibody by overnight incubation at 4◦C. Detection was via
a horseradish peroxidase-linked secondary antibody (Dako)
and ECL (enhanced chemiluminescence) plus reagents (GE
Healthcare), following the manufacturer’s protocol. Autoradio-
grams of immunoblots were digitized on an Image Scanner
(Amersham) and individual protein bands were quantiﬁed
with ImageJ software (http://rsb.info.nih.gov/nih-image/Default.
html). Any differences in protein phosphorylation due to
variations in loading were routinely corrected by normalizing
to the levels of the appropriate total protein.
Cell migration
Transwell cell culture inserts made of transparent low-pore-
density PET (polyethylene terephthalate) with an 8 μm pore size
(Falcon; BD Biosciences) were inserted into a 24-well plate.
Serum-free medium supplemented with or without 25 ng/ml
VEGF-A165 or vehicle was placed in the bottom chamber and
HUVECs in suspension (1.5×10
5 cells/well in serum-free EBM)
were added to the top chamber and incubated at 37◦Ci nf o r4h .
c   The Authors Journal compilation c   2010 Biochemical Society © 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.Novel protein kinase D inhibitor characterization 567
HUVECs that had not migrated or had only adhered to the upper
side of the membrane were removed before membranes were
ﬁxed and stained with a Reastain Quik-Diff kit (IBG Immucor)
using the manufacturer’s protocol and mounted on to glass slides.
HUVECs that had migrated to the lower side of the membrane
were counted in four random ﬁelds per well at ×20 magniﬁcation
using an eye-piece-indexed graticule.
Proliferation
Cell proliferation was assessed by direct counting as described by
Liuetal.[19].Brieﬂy,3.2×10
4 cells/mlwereallowedtoattachto
gelatin-coated 24-well plates for 4 h. Then the complete medium
was then replaced with 0.5% FBS/EBM with 2.5 μMC R T 5o r
vehicle. After 30 min, cells were treated with 25 ng/ml VEGF
or vehicle. After 48 h, cells were trypsinized and counted using a
Sysmex CDA-500 cell counter.
Tubulogenesis
Cell culture plates (12-well) were coated (750 μl per well) with
PureCol Collagen (Nutacon) solution [80% (v/v) in 0.01 M
NaOH and M199 medium], which was allowed to solidify
at 37◦C. HUVECs, transiently transfected with siRNA (small
interfering RNA) as indicated, were then suspended in EBM
containing 0.3% F B S ,a n do v e r l a i do nt ot h eg e l( 1 ×10
5
cells/well) in the presence or absence of 25 ng/ml VEGF and
incubated for 16 h at 37◦C. Digital photographs of cells were
collected using the OpenLab Improvision system. Representative
ﬁelds were selected and photos were taken of each well at ×10
magniﬁcation. The area of linear tubule formation was calculated
using Image J software. Areas of tubule formation were averaged
between four ﬁelds of view and expressed as percentages of
control untreated cells.
Transfection with PKD siRNA
Speciﬁc siRNAs targeting PKD1 and PKD2 (Ambion) were
resuspended in nuclease-free water to yield a stock concentration
of 50 μM. HUVECs in six-well plates were allowed to reach
∼70% conﬂuence before transfection. Both PKD1 and PKD2
siRNAs were diluted to 1 μM each and combined with Opti-
MEM medium (Invitrogen), containing no serum or antibiotics,
and incubated for 25 min with 10 μl of Oligofectamine
TM
reagent (Invitrogen) in a total volume of 200 μl. Thereafter,
HUVEC monolayers were washed with Opti-MEM medium and
the complexes were added on to the cells at a ﬁnal siRNA
concentration of 200 nM each. In parallel wells, Silencer
TM
control siRNA (Ambion), which is a non-targeting scrambled
siRNA, was used at 400 nM. After transfection for 4 h, 10%
(v/v) FBS was added to the medium and was incubated overnight.
The medium was then replaced with complete EBM and the cells
incubated for a further 24 h. The knockdown of PKD1 and PKD2
was then conﬁrmed by immunoblotting.
Statistical methods
Statistical analysis of the differences in phosphorylation
and migration was performed using one- or two-way
ANOVA with post-hoc analysis using Bonferroni’s test where
appropriate. Results are shown as means+ −S.E.M. and P<0.05
was considered signiﬁcant. Where necessary, results were
logarithmicallytransformedpriortoanalysis,tosatisfythecriteria
forANOVAnon-linearregressionanalysis,usingGraphPadPrism
software.
RESULTS
Toxicity, sensitivity and speciﬁcity of the PKD inhibitor
Initial screening of a diverse library containing approx. 55000
compounds in an in vitro assay of PKD1 kinase activity identiﬁed
severalcompoundsthatinhibitedtheactivityofPKD1.Ofinterest
were pyridine benzamides and pyrazine benzamides, all with
the core structure depicted in Figure 1(A) [18], including the
compoundCRT5(structureshowninFigure1A).Thecytotoxicity
of CRT5 was determined in HUVECs using an MTT-based assay.
These results showed that CRT5 had an LD50 value of 17 μM
as established by non-linear regression analysis (Figure 1B),
which was very similar to the cytotoxicity of this compound
in cancer cell lines (results not shown). The biochemical IC50
value of CRT5, as determined by inhibition of peptide substrate
phosphorylation, was similar for all three PKD isoforms at 1,
2 and 1.5 nM for PKD1, PKD2 and PKD3 respectively. The
speciﬁcity of CRT5 for PKD was also initially determined in
an in vitro kinase assay, which included PKCα,P K C δ and
PKCε, the major PKC isoforms expressed in HUVECs [20]. At
1 μM, CRT5 completely inhibited PKD1 and PKD2 as expected,
but had little inhibitory effect on any of the PKC isoforms
tested (Table 1). In addition, in a multi-kinase screen, CRT5
at 1 μM had little effect (<15% inhibition) on the activity of
other serine/threonine and tyrosine protein kinases, including
aurora-A,calmodulin-activatedkinase1,Cdk2(cyclin-dependent
kinase 2), c-Raf, c-Src, EGFR (EGF receptor), GSK3β (glycogen
synthase kinase 3β), IKKα (IκBk i n a s eα), JAK (Janus kinase)-2,
MAPKAPK2,MEK(MAPK/ERKkinase)-1,PAK(p21-activated
kinase)-2, PDGFR (platelet-derived growth factor receptor)-β,
Akt/PKBα (protein kinase Bα), ROCK (Rho-associated kinase)-
2 and RSK (ribosomal S6 kinase)-1. Treatment of HUVECs with
5 μM CRT5 inhibited VEGF-induced phosphorylation of PKD1
at Ser
916 and PKD2 at the corresponding site, Ser
876 (Figure 1C).
In contrast, PKD phosphorylation at Ser
744/Ser
748 was completely
unaffected by CRT5 treatment, whereas the non-selective PKC
inhibitor, GF109203X completely inhibited phosphorylation at
these sites but caused little decrease in phosphorylation at
Ser
916/Ser
876. The differential effects of CRT5 and GF109203X
on PKD phosphorylation are readily explained by the lack of
effect of CRT5 on PKC-dependent PKD phosphorylation, and
CRT5 inhibition of subsequent PKD activity, demonstrated by
the reduction in PKD autophosphorylation at Ser
916/Ser
876.
CRT5 inhibits PKD substrate phosphorylation
To further investigate the effects of CRT5 on PKD activity in
the response of endothelial cells to VEGF, we tested its ability
to inhibit the phosphorylation of proteins previously identiﬁed
as PKD substrates: HSP27 (Ser
82), HDAC5 and CREB. In
endothelial cells two of these substrates, HSP27 and CREB, are
also phosphorylated via the p38 MAPK pathway after VEGF
activation [10,21]. Therefore to distinguish between the role of
PKD and p38 MAPK pathways, we tested CRT5 in the presence
or absence of the p38 MAPK inhibitor SB203580.
VEGF increased HSP27 phosphorylation at Ser
82 approx.
4-fold. CRT5 alone, signiﬁcantly reduced VEGF-induced HSP27
Ser
82 phosphorylation, similar to the effect seen with the PKC
inhibitor GF109203X alone (Figure 2A). Importantly, CRT5 in
combination with SB203580 completely blocked HSP27 Ser
82
phosphorylation, whereas SB203580 and CRT5 alone caused
only partial inhibition (Figure 2A). The effect of CRT5 is
therefore strikingly similar to the effect of GF109203X, which, in
combination with SB203580, also completely abrogated HSP27
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Figure 1 Structure, toxicity and speciﬁcity of CRT5
(A)CorestructureofPKDpyridinebenzamide(upperpanel)andpyrazinebenzamideinhibitors,
where R indicates one of several different functional groups, and X is either a nitrogen (N)
or carbon covalently linked to a functional group (C–R). Further details of the structure of
these compounds are provided in [18]. The structure of CRT5 is shown in the lower panel. (B)
HUVECs were incubated with CRT5 (5 nM–100μM) for 24h. Cell viability was estimated by
an MTT-based assay and plotted against the log CRT5 concentration. Non-linear regression
analysis was used to determine the LD50 value. (C) Conﬂuent HUVECs were pre-incubated for
30minwithvehicle(Cont;0.1%DMSO),5 μMSB203580(SB),3μMGF109203X(GF),5μM
SB203580 plus 3μM GF109203X (SB&GF) or 5μM CRT5 with and without 5μM SB203580
(CRT5&SB and CRT5 respectively) as indicated. This was followed by 10min stimulation with
vehicle (C) or 25ng/ml VEGF (V). Cell lysates were immunoblotted and probed with antibodies
against phospho-PKD1 (Ser916 or Ser744/Ser748), phospho-PKD2 (Ser876) or total PKD as
indicated.
Ser
82 phosphorylation (Figure 2A), and also similar to the
inhibitory effects of PKD knockdown using targeted siRNA,
as previously reported by us [10]. Unlike HSP27 Ser
82, HSP27
Ser
78 is not phosphorylated via PKD but is activated through
the p38 MAPK pathway [10]. Consistent with PKD-independent
VEGF-induced Ser
78 phosphorylation, CRT5 or GF109203X had
no effect on Ser
78 phosphorylation, whereas SB203580 alone
completely inhibited it (Figure 2B). In addition, CRT6, an
analogue of CRT5 with the same core structure, that causes no
Table 1 Kinase speciﬁcity of CRT5
In vitro kinase assays showed that, at 1 μM, CRT5 strongly inhibited PKD but had little effect
on a range of PKC isoforms.
Kinase Inhibition (% at 1μM CRT5)
PKCα 5
PKCβI <1
PKCβII <1
PKCγ 23
PKCδ 1
PKCε <1
PKCη< 1
PKCι 10
PKC  2
PKCξ< 1
PKD1 98
PKD2 96
inhibition of PKD at equivalent concentrations in vitro (results
not shown), had no effect on either PKD Ser
916 or HSP27 Ser
82
phosphorylation at 5 μM( F i g u r e2 C ) .
The effect of CRT5 on CREB phosphorylation was similar
to that seen with HSP27 Ser
82 phosphorylation. CRT5 alone
partially reduced the VEGF-induced CREB phosphorylation, in
a similar manner to GF109203X, whereas SB203580 caused no
signiﬁcant decrease in CREB phosphorylation. However, CRT5
in combination with SB203580 caused a more marked inhibition
of VEGF-induced CREB phosphorylation, and GF109203X with
SB203580alsoinhibitedthisresponsemorestrongly(Figure3A).
VEGF-induced HDAC5 phosphorylation was strongly
inhibited by 5 μM CRT5, but, in contrast with HSP27 and CREB
phosphorylation, the combination of CRT5 and SB203580 had
no additional inhibitory effect. SB203580 alone had no inhibitory
effect, conﬁrming that HDAC5 is not activated via the p38
MAPK pathway. Interestingly, GF109203X, either alone or in
combination with SB203580, also had no signiﬁcant inhibitory
effectonVEGF-inducedHDAC5phosphorylation(Figure3B),in
contrastwithpreviousreports[11].SimilartotheeffectsofCRT5,
in parallel cell cultures and treatments, knockdown of PKD1
and PKD2 in HUVECs using siRNA also signiﬁcantly inhibited
VEGF-induced CREB and HDAC5 phosphorylation (Figure 4).
PKD inhibition inhibits VEGF-induced migration, proliferation and
in vitro angiogenesis
VEGF induced a 5.8-fold increase in directed cell migration
comparedwithvehicle(Figure5A)andpre-treatmentofHUVECs
with CRT5 resulted in a signiﬁcant reduction (by 42–51%)i n
the migratory response towards VEGF (Figure 5A). In contrast,
the inactive CRT5 analogue CRT6 had no signiﬁcant effect on
HUVECmigration.Wealsoveriﬁedthat,similarlytoourprevious
results[10],knockdownofPKD1andPKD2signiﬁcantlyreduced
VEGF-stimulated endothelial cell migration with a similar effect
to that of CRT5 tested in parallel cell cultures and treatments
(Figure 5B). VEGF treatment of HUVECs resulted in a 1.5-fold
increase in cell proliferation over 48 h compared with controls
(Figure 5C), and this increase was completely inhibited by pre-
incubationwith2.5 μMCRT5.CRT5causedsomedecreaseinthe
proliferationofcontrolcellsnottreatedwithVEGF,butthiseffect
wasnotstatisticallysigniﬁcant.VEGFinduceda2-foldincreasein
HUVEC tubule formation in a collagen-based assay (Figure 5D);
CRT5 also markedly inhibited VEGF-induced tubulogenesis, but
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Figure 2 Effect of CRT5 on HSP27 phosphorylation
(A) Conﬂuent HUVECs were pre-incubated for 30min with vehicle (Cont; 0.1% DMSO), 5μM
SB203580(SB),3μMGF109203X(GF),5μMSB203580plus3μMGF109203X(SB&GF)or
5 μMCRT5withandwithout5μMSB203580(CRT5&SBandCRT5respectively)asindicated.
Thiswasfollowedby10minstimulationwithvehicle(C)or25ng/mlVEGF(V).Celllysateswere
immunoblotted and probed with antibodies against total and phosphorylated HSP27 (Ser82).
Results from four independent experiments were quantiﬁed by scanning densitometry and are
presented as a ratio of HSP27 phosphorylation corrected for total HSP27 (means+ −S.E.M.,
arbitraryunits).Arepresentativeblotcorrespondingtothequantiﬁedresultsisshownabovethe
histogram. Two-way ANOVA indicated signiﬁcant treatment, inhibitor and treatment–inhibitor
interaction effects (P <0.005). Signiﬁcant differences of interest between treatments and
inhibitors are indicated on the histogram: *P <0.05, **P <0.01 and ***P <0.001 compared
with VEGF alone as determined by Bonferroni’s post hoc test. (B) HUVECs treated as detailed
in (A) were immunoblotted and probed with antibodies against phospho-HSP27 (Ser78)a n d
phospho-PKD2 (Ser876). (C) Conﬂuent HUVECs were pre-incubated for 30min with vehicle
(Cont),5μMSB203580(SB),3μMGF109203X(GF),5μMSB203580plus3μMGF109203X
(SB&GF) or 5μM CRT6 with and without 5μM SB203580 (CRT6&SB and CRT6 respectively)
followed by 10min treatment with vehicle (C) or 25ng/ml VEGF (V). Cell lysates were
immunoblotted and probed with antibodies against PKD phosphorylated at Ser916, HSP27
(Ser82) and total ERK as indicated.
had little effect on basal levels of tubulogenesis (Figure 5D),
whereas CRT6 had no signiﬁcant effect on tubule formation.
DISCUSSION
PKD has recently been implicated in many important cellular
processes, such as proliferation, migration and transcription.
In particular, recent studies have indicated that PKD plays a
major role in VEGF-mediated endothelial cell functions and in
Figure 3 Effect of CRT5 on CREB and HDAC5 phosphorylation
(A)ConﬂuentHUVECswerepre-incubatedfor30 minwithvehicle(Cont.;0.1%DMSO),5μM
SB203580(SB),3μMGF109203X(GF),5μMSB203580plus3μMGF109203X(SB&GF)or
5 μMCRT5withandwithout5μMSB203580(CRT5&SBandCRT5respectively)asindicated.
Thiswasfollowedby10minstimulationwithvehicle(C)or25ng/mlVEGF(V).Celllysateswere
immunoblotted and probed with antibodies against total and phosphorylated CREB (Ser133).
Results from three independent experiments were quantiﬁed by scanning densitometry and
are presented as a ratio of CREB phosphorylation corrected for total CREB (means+ −S.E.M.,
arbitraryunits).Arepresentativeblotcorrespondingtothequantiﬁedresultsisshownabovethe
histogram. Two-way ANOVA indicated signiﬁcant treatment and inhibitor effects (P <0.0001
andP <0.05respectively).Signiﬁcantdifferencesofinterestbetweentreatmentsandinhibitors
are indicated on the histogram: *P <0.05 and **P <0.01 compared with VEGF alone as
determined by Bonferroni’s post hoc test. (B) Effect of CRT5 on HDAC5 phosphorylation.
Cells were treated as detailed for (A). Lysates were immunoblotted and probed with an antibody
againstphospho-HDAC5(Ser489).Resultsfromfourindependentexperimentswerequantiﬁedby
scanning densitometry and are presented as means+ −S.E.M. (arbitrary units). A representative
blot corresponding to the quantiﬁed results is shown above the histogram. Two-way ANOVA
indicated a signiﬁcant treatment effect (P <0.0001). Signiﬁcant differences of interest between
treatmentsandinhibitorsareindicatedonthehistogram:*P <0.05comparedwithVEGFalone
as determined by Bonferroni’s post hoc test.
angiogenesis. Until recently, however, studies of the role of PKD
have been hampered by the lack of speciﬁc inhibitors. While
the present study was in progress, effects of a PKD inhibitor,
CID755673, were reported in a prostate cancer cell line [16].
CRT5 appears to be 100-fold more effective at PKD1 inhibition
compared with CID755673 as determined by its IC50 value.
Furthermore, a recent study found that CID755673 enhances
mitogenic signalling through a PKD-independent pathway
and concluded that this compound cannot be regarded as a
speciﬁc PKD inhibitor [17]. In contrast with CID755673, CRT5,
thePKDinhibitorusedinthepresentstudy,doesnotpreventPKD
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Figure 4 Inhibition of PKD substrate phosphorylation by CRT5 and PKD
knockdown
(A) HUVECs were transfected with 200nM siRNA targeting PKD1 and PKD2, or 400nM of a
control siRNA (Scr). At 48h after transfection, cells were then treated for a further 10 min with
no addition (C) or with 25ng/ml VEGF (V). In parallel cell cultures, conﬂuent HUVECs were
pre-incubated for 30min with either vehicle (Cont; 0.1% DMSO) or 5μM CRT5, followed by
10minstimulationwithvehicle(C)or25ng/mlVEGF(V).Celllysateswerethenimmunoblotted
withantibodiesagainsttotalandphosphorylatedHSP27(Ser82).KnockdownofPKD1andPKD2
wasconﬁrmedusinganantibodythatrecognizesbothPKD1andPKD2[10].Resultsfromatleast
three independent experiments were quantiﬁed by scanning densitometry and are presented as
theratiosofphospho-HSP27tototalHSP27(means+ −S.E.M.,arbitraryunits).Arepresentative
blot corresponding to the quantiﬁed results is shown above the histogram. Two-way ANOVA
indicatedasigniﬁcantinteractionandtreatmenteffects(P <0.05andP <0.0001respectively);
*P <0.05 compared with VEGF plus Scr siRNA or VEGF plus vehicle as determined by
Bonferroni’s post hoc test. (B) HUVECs treated as detailed in (A) were immunoblotted with
antibodies against total or phosphorylated CREB. Two-way ANOVA indicated a signiﬁcant
interaction, inhibitor and treatment effect (P <0.005); *P <0.01 compared with VEGF control
siRNA or VEGF vehicle respectively as determined by Bonferroni’s post hoc test. (C) HUVECs
treated as detailed in (A) were immunoblotted with antibodies against total or phosphorylated
HDAC5. Two-way ANOVA indicated a signiﬁcant inhibitor and treatment effects (P <0.05 and
P <0.001 respectively);*P <0.05 compared with Scr siRNA plus VEGF or vehicle plus VEGF
as determined by Bonferroni’s post hoc test.
phosphorylation by PKC, as shown by the lack of effect
on VEGF-induced Ser
744/Ser
748 phosphorylation. CRT5 does,
however, inhibit PKD kinase activity in vitro, and in intact
endothelial cells, prevents the autophosphorylation of PKD1 and
PKD2 at Ser
916 and Ser
876 respectively. This is in marked contrast
with the effects of the widely used PKC inhibitor GF109203X,
which strongly inhibited Ser
744/Ser
748 phosphorylation but had
little effect on PKD autophosphorylation. The concentrations
at which CRT5 inhibited PKD in intact endothelial cells
are higher than those that inhibited PKD in cell-free assays
using recombinant PKD. Such a difference is not unusual for
pharmacological agents targeting intracellular enzymes and most
likely reﬂects the cellular metabolism of CRT5 and/or its ability
to penetrate the cell membrane. The differential effects of CRT5
and GF109203X, together with the in vitro kinase assay results,
support the conclusion that the effect of CRT5 is highly unlikely
to be due to inhibition of PKC activity. The speciﬁcity of CRT5
was further demonstrated by the observation that, although
it partially inhibited HSP27 Ser
82 phosphorylation, it did not
inhibit VEGF-stimulated HSP27 Ser
78 phosphorylation, which
is mediated via the p38 MAPK pathway in a PKD-independent
manner. We have not investigated whether CRT5 also inhibits
PKD3, but results from our previous study indicated that this
isoform was not involved in either VEGF-induced HSP27
phosphorylation or migration [10].
It has been proposed recently that Ser
916 phosphorylation
may not be an unambiguous marker of PKD activity [22].
It was therefore important to test whether CRT5 could block
activation of known PKD substrates. HSP27 Ser
82 has a strong
consensus PKD phosphorylation site and is an established
downstream target of PKD in vitro and in cells [9,10]. Consistent
with these results, CRT5 pre-incubation reduced HSP27 Ser
82
phosphorylation with an effect very similar to that seen with the
non-selective PKC inhibitor GF109203X, both in the presence
and absence of the speciﬁc p38 MAPK inhibitor SB203580,
suggesting that both CRT5 and GF109203X act on the same
pathway. A notable feature of these ﬁndings is that, although
CRT5andSB203580actingalonecausedonlypartialinhibitionof
HSP27Ser
82 phosphorylation,thecombination of theseinhibitors
completely blocked Ser
82 phosphorylation, consistent with the
effects of GF109203X [10]. Furthermore, the effects of PKD
inhibition on VEGF-induced HSP27 Ser
82 phosphorylation are
in agreement with those seen when PKD expression is reduced
by siRNA [10]. The VEGF-induced phosphorylation of two
other recently identiﬁed PKD substrates, CREB and HDAC5,
was also inhibited by CRT5. The conclusion that the inhibitory
effects of CRT5 on VEGF-stimulated phosphorylation of HSP27
Ser
82, CREB and HDAC5 are mediated via inhibition of PKD
is supported by the observation that targeted knockdown of
PKD1 and PKD2 using siRNAs had a very similar inhibitory
effect when compared directly with CRT5 in parallel cell
cultures. Although we cannot preclude the possibility that PKD
knockdown could have additional effects not caused by kinase
inhibition, possibly mediated via kinase-independent protein–
protein interactions, the effects of PKD siRNA treatment and
CRT5 were in good agreement. The effects of CRT5 on CREB
phosphorylation were broadly similar to those seen on HSP27
Ser
82, with greater inhibition occurring in the combined presence
of CRT5 with SB203580. In contrast, HDAC5 phosphorylation
was strongly inhibited by CRT5 alone, with SB203580 having
no additional effect. Surprisingly, GF109203X also had no effect
on HDAC5 phosphorylation, in contrast with results published
previously [11]. The reason for this discrepancy is unclear,
but it may be explained by differences in HDAC5 regulation
between bovine aortic endothelial cells as used by Ha et al.
[11] and HUVECs used in the present study. In addition, it may
signify that VEGF can additionally activate PKD via a PKC-
independent pathway in these cells. For example, it has been
reported that PKD can be activated by phosphorylation at Tyr
463,
which is mediated by the Src pathway and independent of PKC
c   The Authors Journal compilation c   2010 Biochemical Society © 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.Novel protein kinase D inhibitor characterization 571
Figure 5 Effect of CRT5 on VEGF-induced migration and tubulogenesis
(A) HUVECs were trypsinized and incubated for 30min in the presence of vehicle (Cont; 0.08% DMSO), 1–5μMC R T 5o r5μM CRT6 before being added to the upper chamber of a Transwell
migration assay chamber. Vehicle (C) or 25ng/ml VEGF (V) was added to the lower chamber and the cells were allowed to migrate at 37◦C. After 4 h, the inserts were ﬁxed, stained and migrated
cellswerecounted.Quantiﬁedresultsareexpressedasthemeannumberofcellsmigratingperﬁeldforatleastthreeindependentexperiments.Migrationtowardsvehicleisrepresentedbywhitebars
and towards VEGF by black bars. Results were analysed by one-way ANOVA; *P <0.05 compared with vehicle plus VEGF. (B) HUVECs were transfected with 200nM PKD1 and PKD2 siRNA, or
400nM control siRNA (scr), for 48h. In a parallel set of experiments, non-transfected HUVECs were trypsinized and incubated for 30min in the presence of vehicle (Cont; 0.08% DMSO) or 5μM
CRT5. Cells were then used to determine migration in response to 25ng/ml VEGF in a Transwell migration assay as described in the Materials and methods section. Quantiﬁed results are expressed
as the mean number of cells migrating per ﬁeld for at least three independent experiments. Migration towards vehicle is represented by white bars and towards VEGF by black bars. Two-way ANOVA
indicated a signiﬁcant inhibitor, interaction and treatment effects (P <0.0001). Signiﬁcant differences of interest are indicated on the histogram: *P <0.001 compared with scr siRNA plus VEGF or
vehicle plus VEGF respectively as determined by Bonferroni’s post hoc test. (C) HUVECs were seeded at a density of 3.2×104 cells/ml and allowed to attach to a gelatin-coated 24-well plate for 4h.
The complete medium was then replaced with 0.5% FCS/EBM with 2.5 μM CRT5 or vehicle (Cont) or 10% (v/v) FCS/EBM (grey bar). After 30 min, cells were treated with 25ng/ml VEGF (black
bars) or vehicle (white bars) as indicated. After 48h, cells were trypsinized and counted using a Sysmex CDA-500 cell counter. The results are expressed as the fold increase in cell number from
the original seeding density and are means+ −S.E.M. for three independent experiments. Results were analysed by one-way ANOVA; *P <0.05 compared with vehicle plus VEGF. (D) HUVECs were
trypsinized and incubated for 30min in the presence of vehicle (Cont; 0.08% DMSO), 5μMC R T 5o r5μM CRT6 in EBM containing 0.3% FCS. Cells were then plated on to a collagen base as
described in the Materials and Methods section. Cells plated on to collagen were then incubated for 16h either with no addition (C, white bars) or with 25 ng/ml VEGF (black bars). Tubulogenesis
was quantiﬁed with ImageJ. ANOVA indicates that CRT5 signiﬁcantly reduced VEGF-mediated tube formation whereas CRT6 had no signiﬁcant effect. *P <0.05 compared with VEGF (no inhibitor)
as determined by Bonferroni’s post hoc test. Values (n3) are means+ −S.E.M., expressed as the area of tubules formed in pixels per ﬁeld.
[23]. This may also explain why GF109203X appears to be
less effective than CRT5 at inhibiting PKD phosphorylation at
Ser
916.
As PKD is thought to play a pivotal role in VEGF-induced
angiogenesis [10,11,15,24], we investigated whether CRT5
could disrupt the mechanisms associated with angiogenesis in
endothelialcells.CRT5markedlyinhibitedthemigrationandpro-
liferation of HUVECs in response to VEGF stimulation and
reduced VEGF-induced in vitro angiogenesis in a collagen-based
assay,whereasitsinactiveanalogueCRT6,whichdoesnotinhibit
PKD at similar concentrations,was unableto signiﬁcantlydisrupt
migration or tube formation. The effects of CRT5 on migration
and tubulogenesis are similar to those seen when PKD1 or PKD2
are knocked down with siRNA [10].
In conclusion, we have shown that CRT5 acts as a speciﬁc
inhibitor of PKD in the response of endothelial cells to VEGF,
providing further support for the conclusion that PKD is an
important mediator of VEGF receptor signalling and biological
functions. This compound and/or its derivatives may have great
potential, both as a biochemical tool and as a starting point for
novel anti-angiogenic therapeutic drug development.
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